secwatch.observer — SEC 8-K summary
======================================

Issuer:     IO Biotech, Inc. (IOBTQ)
CIK:        0001865494
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001193125-23-004173
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IO Biotech: Phase 3 melanoma trial continues; Phase 2 lung cancer shows 4 partial responses; $142.7M cash
--------------------------------------------------------------------------------

- IDMC recommends Phase 3 melanoma trial continue without changes; enrolling at >80 sites globally.
- Initial Phase 2 basket data: 9 evaluable NSCLC patients: 4 partial responses, 4 stable disease, 1 progressive disease.
- New investigator-initiated study with Johns Hopkins for SCCHN expected H1 2023; total 4 IITs ongoing.
- Preliminary cash $142.7M at Dec 31, 2022; expected to fund operations into mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865494/000119312523004173/0001193125-23-004173-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865494/000119312523004173/d448682d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-004173

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer